Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.

A simplified schedule of high-dose chemotherapy (HDC) consisting of melphalan (140 mg m-2) plus VP16 (2.5 g m-2) given over 12-18 h together with autologous non-cryopreserved autologous bone marrow transplant (ABMT) was used for treatment of relapsed (37 patients) and refractory (seven patients) pat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Seymour, L. K., Dansey, R. D., Bezwoda, W. R.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1994
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2033336/
https://ncbi.nlm.nih.gov/pubmed/8080741
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki